Document is current
Any future updates will be listed below
-
Authors
Goldstein, Rachel https://orcid.org/0000-0001-8199-3080
Sandouka, Khaled https://orcid.org/0009-0004-0177-2069
Zighan, Lana https://orcid.org/0000-0002-4215-1806
Ya’ari, Shaul https://orcid.org/0000-0002-4984-7689
Bialer, Meir https://orcid.org/0000-0003-2046-4171
Muszkat, Mordechai https://orcid.org/0000-0002-9520-1379
-
Funding
Funding for this research was provided by:
Ministry of Science and Technology, Israel
Hebrew University of Jerusalem
- License Information
-
More Information
Article History
Received: 10 December 2025
Accepted: 20 January 2026
First Online: 14 February 2026
Declarations
:
: Meir Bialer received in the last 5 years consultancy fees from Angelini Pharma, Clexio Therapeutics, Guidepoint, Meditec (Sam On), NeuroSense Therapeutics, Pharma2B, Selene Therapeutics, Shackelford Pharma, and Xenon Pharmaceuticals. Mordechai Muszkat received honoraria from Roche and a research grant from the Pfizer Independent Global Medical Grant. Rachel Goldstein, Khaled Sandouka, Lana Zighan, and Shaul Yaari have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: The datasets analyzed during the study are not publicly available because of institutional and patient privacy regulations, but are available from the corresponding author upon reasonable request and with permission from Hadassah Medical Center.
: Not applicable.
: RG, KS, LZ, MM, and MB conceived and designed the study, collected and analyzed the data, and drafted the manuscript. RG, KS, and MM contributed to data analysis and interpretation. SY, MM, and MB provided supervision and critical revision of the manuscript. All authors read and approved the final manuscript.
